David Leppert, MSVirtual2020 – Potential of Neutrophil Granulocyte Markers in CSF to Differentiate NMOSD and MOGAD from MS
It was a pleasure to hear from David Leppert (University Hospital Basel and University of Basel, Basel, Switzerland) on his late-breaking presentation about the exciting potential of neutrophil granulocyte markers in the cerebrospinal fluid to differentiate neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) from multiple sclerosis (MS) in the acute disease phase.
- Briefly, what are the clinical and pathological similarities between neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and multiple sclerosis (MS)? (0:06)
- What methods have been used in the past to distinguish these conditions and what are the limitations of these methods? (2:16)
- Could you give us an overview of the rationale for and design of your study investigating neutrophil granulocyte markers in cerebrospinal fluid? (3:38)
- What were the major findings of your study? (6:11)
- What is the potential impact of these findings on clinical practice and what future studies are planned? (7:16)
Disclosures: David Leppert has been Therapeutic Area Head at Novartis, Neuroscience Development Unit, until January 2019. He is Senior Research Associate at the Department of Neurology at University Hospitals Basel, and Chief Medical Officer of GeNeuro. He has received personal compensation for consulting and speaking, and travel reimbursement from Quanterix, Orion, Novartis, Roche and Sanofi.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
Share this Video
Related Videos In Neuroimmunology
Michael Levy: Highlights from the 75th AAN Annual Meeting, 2023
Dr Michael Levy (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) provides his highlights from the 75th AAN Annual Meeting, 2023, in particular that this was the first year to have a myelin oligodendrocyte glycoprotein (MOG) antibody disease focus, with posters on two phase 3 trials, which are expected to be presented in 2026. Disclosures: […]
Michael Levy, AAN 2023: Phase 3 CHAMPION-NMOSD subgroup analyses in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
CHAMPION-NMOSD (NCT04201262) is a study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Ravulizumab binds to the same complement component 5 epitope as eculizumab; however, its longer elimination half-life extends the dosing interval (every 8 versus 2 weeks). In this touchNEUROLOGY interview, we caught up with Dr Michael Levy (Massachusetts General Hospital, […]
Sean Pittock, ECTRIMS 2022: Subgroup analyses from the phase 3 CHAMPION-NMOSD investigating ravulizumab for neuromyelitis optica spectrum disorder
The CHAMPION-NMOSD trial (NCT04201262) is a global, open-label, multicentre, phase 3, externally controlled study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD). In this touchNEUROLOGY interview, we caught up with Prof. Sean Pittock (Mayo Clinic, Rochester, MN, USA) to discuss the pre-specified efficacy analyses in clinically relevant patient subgroups, and the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!